ESTRO 2025 - Abstract Book

S569

Clinical - Breast

ESTRO 2025

Mean heart dose and mean LAD dose were similar among patients reporting or not a reduction of LVEF > 10% (3.12 Gy vs 2.56 Gy, p= 0.561; 5.83 Gy vs 5.49 Gy, p=0.867 respectively) (figure 1).

Conclusion: In this contemporary real life retrospective cohort of patients treated with chemotherapy and Trastuzumab Pertuzumab combination, postoperative radiotherapy seems not to worsen cardiotoxicity related to modern anti her2 therapies. Further prospective studies are needed to confirm these findings.

Keywords: pertuzumab, radiotherapy, cardiotoxicity

References: Meattini I, Becherini C, Caini S, Coles CE, Cortes J, Curigliano G, de Azambuja E, Isacke CM, Harbeck N, Kaidar-Person O, Marangoni E, Offersen BV, Rugo HS, Salvestrini V, Visani L, Morandi A, Lambertini M, Poortmans P, Livi L; Consensus Panellist Group. International multidisciplinary consensus on the integration of radiotherapy with new systemic treatments for breast cancer: European Society for Radiotherapy and Oncology (ESTRO)-endorsed recommendations. Lancet Oncol. 2024 Feb;25(2):e73-e83. doi: 10.1016/S1470-2045(23)00534-X. PMID: 38301705.

3324

Digital Poster Complications after photon vs proton radiotherapy for breast cancer treated with mastectomy and immediate reconstruction Chris E. Vrieling 1 , Pieter R.A.J. Deseyne 1 , Iris L. Holt-Kedde 2 , Vera C. van Aalst 2 , Johannes A. Langendijk 1 , John H. Maduro 1 , Anne P.G. Crijns 1